Nymox Announces New Clinical Data from BPH Drug Trials to Be Presented at Upcoming U.S. Urology MeetingHASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Aug 21, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that further clinical results from the Company's studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the meeting of the Western Section of the American Urological Association (AUA) to be held in Scottsdale, Arizona in October. The paper is authored by leading clinical research investigators from U.S. clinical trials of NX-1207. Further specific details on the upcoming presentation will be announced at a later date.
The Company previously completed three U.S. trials for NX-1207, including most recently a Phase 2 double-blind, placebo controlled, randomized multi-site U.S. study, which showed positive efficacy and safety results for NX-1207 after 3 months in patients with BPH. Overall, patients treated with NX-1207 showed after 3 months a mean improvement of 9.35 points in AUA Symptom Score values, the standard scale used to evaluate BPH drugs and treatments. This improvement compares favorably to the 3.5 to 5 point reported in published studies of currently approved drugs for BPH and reached statistical significance when compared to placebo. Subjects treated with NX-1207 also showed an overall statistically significant reduction in mean prostate volume. The results of the trial demonstrated the excellent safety and side effect profile of NX-1207. Subjects treated with NX-1207 had no serious side effects. In particular, patients given NX-1207 had no (0%) significant sexual side effects.
The Company previously announced that papers concerning NX-1207 clinical studies will be presented in September at the meeting of the South Central Section of the AUA in Colorado Springs and at the meeting of the New England Section of the AUA in Boston and in October at the meeting of the Mid-Atlantic Section of the AUA in Bermuda.
The company also recently reported positive long-term outcome results from an 8-19 month study of 116 unselected subjects from 26 U.S. clinical sites in a blinded placebo-controlled study, which reached statistical significance (p=.028). In that study, overall without further NX-1207 treatment, patients initially treated with NX-1207 showed a total pooled mean improvement of 7.4 points in the primary outcome endpoint of AUA Symptom Score values.
The AUA Symptom Score is a standardized measurement of BPH symptoms and includes data on 1) sensations of incomplete emptying of the bladder; 2) need to urinate frequently; 3) stopping and starting during urination; 4) urgent need to urinate; 5) weakness of urinary stream; 6) need to push or strain during urination; and 7) urination during sleep (nocturia). Published studies of currently approved drugs for BPH show AUA Symptom Score improvement in the 3.5 to 5 point range.
BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.
More information about Nymox is available at www.nymox.com, email: firstname.lastname@example.org, or 800-936-9669.
This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
Nymox Pharmaceutical Corporation
Roy Wolvin, 1-800-93NYMOX
Posted: August 2007